Relay Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Relay Therapeutics, Inc. (RLAY) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$1.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-08-06
- Relay Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-06-30 was -$1.38M.
- Relay Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-03-31 was -$905.00K, a 187.95% decline year-over-year.
- Relay Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-09-30 was $656.00K, a 82.96% decline year-over-year.
- Relay Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-06-30 was -$201.00K.
- Relay Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2025 was $1.72M.
- Relay Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2024 was -$795.00K, a 107.78% decline from fiscal 2023.
- Relay Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2023 was $10.22M.
- Relay Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was -$9.33M.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.38M 10-Q · filed 2026-08-06 | -$2.29M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$905.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $1.72M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $656.00K 10-Q · filed 2025-11-06 | $455.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.48M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$201.00K 10-Q · filed 2026-08-06 | $828.00K derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $1.03M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | -$795.00K 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $3.85M 10-Q · filed 2025-11-06 | $3.67M derived: sum of 2 quarters · filed 2025-11-06 | $2.71M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | -$182.00K 10-Q · filed 2025-11-06 | -$1.14M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | -$962.00K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $10.22M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $2.69M 10-Q · filed 2024-11-06 | $2.42M derived: sum of 2 quarters · filed 2024-11-06 | $7.03M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | -$279.00K 10-Q · filed 2024-11-06 | $4.34M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $4.62M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | -$9.33M 10-K · filed 2025-02-26 | |||
| 2022-09-30 | -$1.48M 10-Q · filed 2023-11-02 | -$4.17M derived: sum of 2 quarters · filed 2023-11-02 | -$12.30M derived: sum of 3 quarters · filed 2023-11-02 | |
| 2022-06-30 | -$2.69M 10-Q · filed 2023-11-02 | -$10.82M derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2022-03-31 | -$8.13M 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | -$1.15M 10-K · filed 2024-02-22 | |||
| 2021-09-30 | $74.00K 10-Q · filed 2022-11-03 | -$2.00K derived: sum of 2 quarters · filed 2022-11-03 | -$54.00K derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | -$76.00K 10-Q · filed 2022-11-03 | -$128.00K derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | -$52.00K 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | -$261.00K 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |